三药雾化吸入联合孟鲁司特治疗喘息型支气管肺炎的临床研究  

CLINICAL ANALYSIS OF THE EFFECT OF THREE DRUGS ATOMIZATION COMBINED WITH MONTELUKAST IN THE TREATMENT OF ASTHMATIC BRONCHOPNEUMONIA

作　　者：付家林 姚小飞 Fu Jialin;Yao Xiaofei(Department of Pediatrics,Ma'anshan Shiqiye Hospital,Mafanshan 243000,China)

机构地区：[1]安徽省马鞍山市十七冶医院儿科

出　　处：《中国煤炭工业医学杂志》2019年第5期498-501,共4页Chinese Journal of Coal Industry Medicine

基　　金：安徽省卫生计生委科研计划项目(编号:2017ek009)

摘　　要：目的探讨布地奈德、异丙托溴铵与特布他林三药雾化吸入治疗联合孟鲁司特在喘息型支气管肺炎患儿中的临床应用价值。方法回顾性分析2016年12月-2017年6月马鞍山市十七冶医院儿科收治的90例喘息型支气管肺炎患儿的病历资料。按治疗方式的不同分为A组(32例,采用布地奈德、异丙托溴铵与特布他林三药雾化联合口服孟鲁司特治疗)、B组(26例,采用布地奈德与异丙托溴铵或特布他林两药雾化治疗)、C组(32例,采用布地奈德、异丙托溴铵与特布他林三药雾化治疗)。对比分析不同治疗方式的临床治疗效果及不良反应。结果经治疗后,A组的咳嗽缓解时间、喘憋消失时间和啰音消失时间均明显短于B组和C组,且C组上述指标均短于B组,差异均有统计学意义(P<0.05)。经治疗后,A、B、C组的CRP水平及A组和C组的WBC水平均明显降低,与治疗前比较差异有统计学意义(P<0.05)。A组治疗后的CRP和WBC水平均明显低于B组和C组,且C组上述指标均低于B组,差异均有统计学意义(P<0.05)。各组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德、异丙托溴铵与特布他林三药雾化治疗联合口服孟鲁司特,对于治疗喘息型支气管肺炎疗效更佳,值得临床推广。Objective To explore the clinical application value of budesonide,ipratropium bromide and terbutaline combined with montelukast in patients with asthmatic bronchopneumonia.Methods Ninety cases of asthmatic bronchopneumonia who were admitted to Ma′anshan Shiqiye Hospital from December 2016 to June 2017 were retrospectively analyzed.According to the different treatment methods,the patients were divided into group A(32 cases,treated with budesonide,ipratropium bromide and terbutaline combined with montelukast),group B(26 cases,treated with budesonide and ipratropium bromide or terbutaline),and group C(32 cases,treated with budesonide,ipratropium bromide and terbutaline).The clinical effects and adverse reactions of different treatment methods were compared and analyzed.Results After treatment,the cough remission time,wheezing disappearance time and rale disappearance time of group A were significantly shorter than those of group B and C,and the above indexes of group C were shorter than those of group B,the difference was statistically significant(P<0.05).After treatment,CRP levels in group A,B and C and WBC levels in group A and C were significantly lower than those before treatment(P<0.05).After treatment,CRP and WBC levels in group A were significantly lower than those in group B and C,and the above indexes in group C were lower than those in group B,with statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions among the groups(P>0.05).Conclusion Budesonide,ipratropium bromide and terbutaline combined with oral montelukast is more effective in the treatment of asthmatic bronchopneumonia and worthy of clinical promotion.

关 键 词：布地奈德 异丙托溴铵 特布他林 雾化吸入 孟鲁司特 喘息型支气管肺炎 

分 类 号：R563.12[医药卫生—呼吸系统]